Optometric Management

FEB 2017

Issue link: http://optometricmanagement.epubxp.com/i/781116

Contents of this Issue


Page 35 of 64

33 CLINICAL RE TINA F E B R U A R Y 2 0 1 7 • O P T O M E T R I C M A N A G E M E N T . C O M Superior Coverage for Complete Dry Eye Relief © 2016 OCuSOFT, Inc., Rosenberg, TX 77471 USA Fourth Generation Tear Film Enhancement For more information and to order, call (800) 233-5469 or visit www.ocusoft.com (endophthalmitis) • Retinal detachment • Retina or vitreous bleeding • Small specks or bubble shapes in vision (can be intermittent or permanent.) As bevacizumab costs less for the patient vs. ra- nibizumab, it tends to be a more popular choice. at said, patient assistance programs are available from Genentech (tinyurl.com/retdrug) and Regen- eron (tinyurl.com/eyeret) to help subsidize costs. Something else to keep in mind: Not all injections may be covered by each insurance carrier, so be sure the patient understands it is his or her responsibil- ity, with the assistance of the eye care provider, to determine coverage. WHAT CAN YOU DO? Intravitreal injections of anti-VEGF are now considered the gold standard of therapy in the management of a plethora of retinal conditions. Anti-VEGF treatment modalities are constantly evolving, including a sustained-release treatment. Optimal patient outcomes depend on early diag- nosis, prompt referral to the specialist and man- agement of vision-threatening complications. As optometry is on the forefront of retinal disease,it is imperative that our understanding of how best to use these agents continues to grow, so that we can, in turn, further educate our pa- tients, make informed referrals and management decisions. We are more likely going to see more patients for follow-up care as well, and based on the clinical course of their disease, may need to refer them back to the specialist for subse- quent injections. OM DR. REYNOLDS is an associate professor at the Nova South- eastern University College of Optometry and clinical preceptor/attending in the college's dia- betes and macular clinic. She is a fellow of the Optometric Retina Society and chairperson for the Florida Optomet- ric Association Healthy Eyes Healthy People Committee. Comment at tinyurl.com/OMcomment. MINIMAL DIFFERENCES IN RISK EXIST AMONG ALL THREE DRUGS . . .

Articles in this issue

Links on this page

Archives of this issue

view archives of Optometric Management - FEB 2017